Funder
the Research Fund for Clinical Pharmacy of China International Medical Foundation
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference43 articles.
1. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB et al (2021) Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 384(16):1529–1541
2. Barreca M, Lang N, Tarantelli C, Spriano F, Barraja P, Bertoni F (2022) Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences. Explor Target Antitumor Ther 3(6):763–794
3. Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny MP, Hill SR (2016) Cost-effectiveness thresholds: pros and cons. Bull World Health Organ 94(12):925–930
4. Beth Woods ES, Stephen Palmer, Nick Latimer, Marta Soares: NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. In.: Centre for Health Economics, University of York, York, UK; 2017: 1–72.
5. Cao M, Li H, Sun D, Chen W (2020) Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun (lond) 40(5):205–210